Deal includes co-development of new products and services and distribution rights for GeneMaker.
Invitrogen will invest in Blue Heron in exchange for worldwide rights to distribute the company’s custom gene synthesis services, under a strategic development and distribution deal.
Blue Heron Biotechnology’s GeneMaker® platform can synthesize any gene sequence, with perfect accuracy regardless of length or complexity, which makes it ideal for the synthetic biology market, the companies report.
“Invitrogen recognizes the tremendous new possibilities that gene synthesis offers life science researchers,” says Nathan Wood, vp of cloning and protein expression, Invitrogen. “We have developed a broad array of products that complement Blue Heron’s GeneMaker platform and this agreement continues to enhance our portfolio offerings to our customers.”
As part of the agreement, the companies will co-develop new products and services for the research and biopharmaceutical markets.
